Chr. Hansen and partner Biofarma debut a powerful new probiotic concept: A convenient, drinkable probiotic shot in a user-friendly mini-bottle using the unique DRYCAP® technology. The first off-the-shelf shot is a healthy and tasty solution combining BB-12® and fiber.
The new probiotic shot concept is launched at the CPhI 2013 event held in Frankfurt, Germany October 22-24. Here visitors will have the opportunity to see and taste the probiotic shot containing Chr. Hansen’s flagship probiotic strain BB-12® – the world’s best documented Bifidobacterium – with fiber in the form of fructo-oligosaccharides (FOS). The product, which can be promoted as a “2 in 1” or “dual action” product, addresses gastrointestinal function and irregularities.
“We are really looking forward to showcasing this healthy, lemon-flavored shot that combines two ingredients which both have a long history of use, high consumer awareness and acceptance,” says Chr. Hansen’s Lasse Nagell, Sales & Marketing Vice President, Health & Nutrition.
Unique and patented storage
The attractive combination probiotic and fiber comes in a 10 ml liquid shot format, a convenient dosage form designed for the health-conscious consumer who prefers to drink shots rather than swallow capsules or tablets.
“The consumer simply dispenses the probiotics into the liquid, shakes the bottle to disperse the probiotics, and drinks the shot ? a quick and tasty way to get your probiotics on the go,” Lasse Nagell explains.
“The BB-12® + fiber shot is the first probiotic liquid shot we propose to the market but there are multiple opportunities to combine ingredients in “dual action” shots. It will be interesting to discuss the opportunities with participants at CPhI 2013.”
CPhI 2013 is a leading pharmaceutical networking event. You will find Chr. Hansen and Biofarma at booth no. 41G09.
Read more about CPhI 2013:
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.